Association of folate transporter SLC19A1 polymorphisms with the outcome of multiple myeloma after chemotherapy and tandem autologous transplantation.
Maggini
V
V
Buda
G
G
Galimberti
S
S
Conidi
E
E
Giuliani
N
N
Morabito
F
F
Genestreti
G
G
Iacopino
P
P
Rizzoli
V
V
Barale
R
R
Petrini
M
M
Rossi
A M
AM
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007558:Italy; D008297:Male; D026901:Membrane Transport Proteins / Q000235:genetics*; D008875:Middle Aged; D009101:Multiple Myeloma / Q000235:genetics / Q000628:therapy; D011110:Polymorphism, Genetic; D011379:Prognosis; D058978:Reduced Folate Carrier Protein; D033581:Stem Cell Transplantation; D016019:Survival Analysis; D014182:Transplantation, Autologous
D014408:Biomarkers, Tumor; D026901:Membrane Transport Proteins; D058978:Reduced Folate Carrier Protein; C548699:SLC19A1 protein, human